A Phase 2 interventional study of PF-06651600 and PF-06651600 in Active Non-segmental Vitiligo, sponsored by Pfizer. Completed at 92 sites in 10 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.
Among the 80 studies in Vitiligo with a site in United States, this one is the 8th largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2018, is one of 31 in phase 2, and was the 30th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Poland
Ages 18–65
CorEvitas · Sites in United States
Ages 12+ · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 2 more countries
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–99
Elixiron Immunotherapeutics (Hong Kong) Ltd. · Sites in United States, Taiwan
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 14 · Phase 4 1
First in 1995; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 366 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 37 across the 68 interventional studies, 1,750 across the 12 observational. Of the 50 that completed or were terminated, 25 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 80 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Vitiligo — fewer than ten, so there is no comparison to draw.
8 of the studies in Vitiligo with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06163326Phase 3PfizerA 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | 2027-03-31 |
| NCT06072183Phase 3PfizerA 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 | 2027-07-30 |
| NCT03577327Northwestern UniversityThe Gut and Skin Microbiome in Vitiligo Disease Progression | 2026-12 |
| NCT07223229Elixiron Immunotherapeutics (Hong Kong) Ltd.Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients | 2026-12-31 |
| NCT07108283TakedaA Study of Zasocitinib in Adults With Nonsegmental Vitiligo | 2027-03-26 |
Add all 8 to your calendar (.ics) → With an account.
Among the 80 studies in Vitiligo with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks. This includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week extension period and a 8 week Follow up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
Drug: PF-06651600
Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
Drug: PF-06651600
Maintenance dose A given QD for 24 weeks
Drug: PF-06651600
Maintenance dose B given QD for 24 weeks
Drug: PF-06651600
Maintenance dose C given QD for 24 weeks
Drug: PF-06651600
Placebo given QD for 24 weeks
Drug: placebo
4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
Drug: PF06700841
Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
Drug: PF-06651600 · Device: narrow-band UVB phototherapy
Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
Drug: PF-06651600
Maintenance dose A given QD for 24 weeks
Drug: PF-06651600
Maintenance dose B given QD for 24 weeks
Drug: PF-06651600
Observation period for 24 weeks
Induction dose 1. Oral tablet taken QD
Induction dose 2. Oral tablet taken QD
Maintenance dose A. Oral tablet taken QD
Maintenance Dose B. Oral tablet taken QD
Maintenance Dose C. Oral tablet taken QD
placebo
Oral tablet taken QD
Phototherapy will be combined with PF-06651600
Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period
Central read F-VASI was assessed based on the facial photographs taken at the site. Central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. The higher score of F-VASI signified severer symptoms of non-segmental vitiligo. Percent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)×100. A negative percent change from baseline in central read F-VASI signified an improvement.
Time frame: Baseline, Week 24 (Baseline was defined as the last measurement prior to Study Day 18)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to Week 24 - DR Period
Adverse Event (AE) was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator.
Time frame: 24 weeks
Number of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - DR Period
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline up to Week 24
Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile up to Week 24 - DR Period
Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline up to Week 24
Number of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - DR Period
Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin.
Time frame: 24 weeks
Number of Participants With TEAEs and SAEs - Extension (Ext) Period
AE was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator.
Time frame: 24 weeks
Number of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - Ext Period
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.
Time frame: 24 weeks
Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile - Ext Period
Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator.
Time frame: 24 Weeks
Number of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - Ext Period
Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin.
Time frame: 24 weeks
Percentage of Participants Achieving Central F-VASI75 at Week 24 - DR Period
This outcome measure was the percentage of participants achieving at least 75% improvement from baseline in central read F-VASI (F-VASI75) at Week 24. A negative percent change from baseline in central read F-VASI signified an improvement. The central read F-VASI75 response rate was analyzed by first treating the missing data (non-COVID-19 related) as non responders and then applying Chan and Zhang exact confidence interval (CI) method at Week 24. Central read F-VASI75=1 if percent change from baseline ≥75; central read F-VASI75=0 if percent change from baseline \<75. Percent change from baseline in F-VASI=((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. Baseline was defined as the last measurement prior to study Day 18.
Time frame: Week 24
Percentage of Participants Achieving T-VASI50 at Week 24 - DR Period
Total body VASI (T-VASI) was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: T-VASI= Ʃ\[Hand Units\]×\[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding feet), and feet. The extent of depigmentation was expressed by percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The data below was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50) at Week 24. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Week 24
Percent Change From Baseline in T-VASI at Designated Time Points - DR Period
The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percent Change From Baseline in Central Read F-VASI at Designated Time Points - DR Period
The central read F-VASI was assessed based on the facial photographs taken at the site. The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)×100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
Time frame: Baseline, Weeks 4, 8, 16 and 24
Percent Change From Baseline in Local F-VASI at Designated Time Points - DR Period
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0.00 4.00): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percent Change From Baseline in SA-VES at Designated Time Points - DR Period
The Self-Assessment Vitiligo Extent Score (SA-VES) was a validated patient report outcome measurement instrument to provide information about disease extent. Vitiligo Extent Score (VES) was a measure to express the overall vitiligo involvement of the body (extent). Clinical illustrations for 19 separate body areas that reflected different degrees of involvement (1%, 5%, 10%, 25%, 50% and 75% depigmentation) were chosen to represent the participant's skin lesions to get the total extent of the disease. VES was a sum of all surface measurement that was similar to VASI. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 16 and 24
Absolute Change From Baseline in T-VASI at Designated Time Points - DR Period
The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. The absolute change from baseline in T-VASI was analyzed using the ANCOVA analysis. Negative change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving T-VASI50 at Designated Time Points - DR Period
T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving T-VASI75 at Designated Time Points - DR Period
T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 75% improvement from baseline in T-VASI (T-VASI75). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving T-VASI90 at Designated Time Points - DR Period
T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 90% improvement from baseline in T-VASI (T-VASI90). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving T-VASI100 at Designated Time Points - DR Period
T-VASI was calculated using a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. This outcome measure was the percentage of participants achieving 100% improvement from baseline in T-VASI (T-VASI100). Percent change from baseline in T-VASI = ((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving Central Read F-VASI50 at Designated Time Points - DR Period
The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 50% improvement in central read F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
Time frame: Baseline, Weeks 4, 8, 16 and 24
Percentage of Participants Achieving Central Read F-VASI75 at Designated Time Points - DR Period
The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 75% improvement in central read F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
Time frame: Baseline, Weeks 4, 8, 16 and 24
Percentage of Participants Achieving Central Read F-VASI90 at Designated Time Points - DR Period
The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 90% improvement in central read F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
Time frame: Baseline, Weeks 4, 8, 16 and 24
Percentage of Participants Achieving Central Read F-VASI100 at Designated Time Points - DR Period
The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 100% improvement in central read F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
Time frame: Baseline, Weeks 4, 8, 16 and 24
Percentage of Participants Achieving Local F-VASI50 at Designated Time Points - DR Period
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 50% improvement in site assessment F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving Local F-VASI75 at Designated Time Points - DR Period
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 75% improvement in site assessment F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving Local F-VASI90 at Designated Time Points - DR Period
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 90% improvement in site assessment F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving Local F-VASI100 at Designated Time Points - DR Period
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving 100% improvement in site assessment F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Change From Baseline in Total VitiQoL Score at Designated Time Points - DR Period
The Vitiligo-Specific Quality of Life (VitiQoL) instrument was a reliable and validated vitiligo disease-specific health-related quality of life (HRQoL) instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL total score was calculated as sum of items 1-15. The change from baseline in total VitiQoL score was analyzed using the mixed-effect models repeated measures (MMRM) analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 16 and 24
Change From Baseline in VitiQoL Participation Limitation Domain Score at Designated Time Points - DR Period
The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Participation Limitation domain score was the sum of items 3, 4, 6, 9, 10, 11, 14 and ranged from 0 to 42. The change from baseline in VitiQoL Participation Limitation Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 16 and 24
Change From Baseline in VitiQoL Stigma Domain Score at Designated Time Points - DR Period
The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Stigma domain score was the sum of items 1, 2, 5, 7 and 15, and ranged from 0 to 30. The change from baseline in VitiQoL Stigma Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 16 and 24
Change From Baseline in VitiQoL Behaviors Domain Score at Designated Time Points - DR Period
The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Behaviors domain score was the sum of items 8, 12 and 13, and ranged from 0 to 18. The change from baseline in VitiQoL Behaviors Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Weeks 4, 16 and 24
Percentage of Participants Achieving sIGA 0 or 1 and at Least a 2-Point Improvement at Week 24 - DR Period
The percentage of participants achieving a static Investigator Global Assessment (sIGA) Score 0/1 and sIGA ≥2-point improvement at Week 24 was presented in this outcome measure. The sIGA score ranged from 0 to 4. The sIGA Score 0 represented "Clear" with no signs of loss of pigmentation with natural light or with Woods lamp examination. The sIGA Score 1 represented "Almost Clear" with the following descriptors: * Faint, barely detectable loss of pigmentation mainly located on dorsal hands, feet, bony prominences, and/or limited areas. * Approximately 90% pigmentation within lesions. * No or rare signs of Koebner phenomenon, confetti like or trichrome lesions could be present. The sIGA Scores 2, 3 and 4 represented "Mild Vitiligo", "Moderate Vitiligo" and "Severe Vitiligo", respectively.
Time frame: Week 24
| Milestone | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo | Extension (EXT) PF-06700841 60 mg - 30 mg QD | EXT PF-06651600 200 Mg-50 mg QD + nbUVB | EXT PF-06651600 200 mg - 50 mg QD | EXT PF-06651600 50 mg QD | EXT PF-06651600 30 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 65 | 67 | 67 | 50 | 49 | 66 | 0 | 0 | 0 | 0 | 0 |
| Completed | 53 | 58 | 54 | 36 | 42 | 55 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 12 | 9 | 13 | 14 | 7 | 11 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 4 | 5 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 4 | 3 | 9 | 2 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Medication error without associated adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo | Extension (EXT) PF-06700841 60 mg - 30 mg QD | EXT PF-06651600 200 Mg-50 mg QD + nbUVB | EXT PF-06651600 200 mg - 50 mg QD | EXT PF-06651600 50 mg QD | EXT PF-06651600 30 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 55 | 43 | 187 | 6 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 47 | 27 | 158 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 16 | 29 | 3 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 6 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 9 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 12 | 3 | 0 |
| Withdrew: Medication error without associated adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 0 | 0 |
Central read F-VASI was assessed based on the facial photographs taken at the site. Central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. The higher score of F-VASI signified severer symptoms of non-segmental vitiligo. Percent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)×100. A negative percent change from baseline in central read F-VASI signified an improvement.
| Percent Change | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period | -21.2 ± 4.13 | -21.2 ± 4.16 | -18.5 ± 4.44 | -14.6 ± 5.47 | -3.0 ± 4.65 | 2.1 ± 4.06 |
This outcome measure was the percentage of participants achieving at least 75% improvement from baseline in central read F-VASI (F-VASI75) at Week 24. A negative percent change from baseline in central read F-VASI signified an improvement. The central read F-VASI75 response rate was analyzed by first treating the missing data (non-COVID-19 related) as non responders and then applying Chan and Zhang exact confidence interval (CI) method at Week 24. Central read F-VASI75=1 if percent change from baseline ≥75; central read F-VASI75=0 if percent change from baseline \<75. Percent change from baseline in F-VASI=((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. Baseline was defined as the last measurement prior to study Day 18.
| Percentage of Participants | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Central F-VASI75 at Week 24 - DR Period | 12.1 | 8.5 | 7.7 | 2.7 | 2.3 | 0 |
Total body VASI (T-VASI) was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: T-VASI= Ʃ\[Hand Units\]×\[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding feet), and feet. The extent of depigmentation was expressed by percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The data below was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50) at Week 24. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving T-VASI50 at Week 24 - DR Period | 7.9 | 4.6 | 4.6 | 10.6 | 4.1 | 9.1 |
The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percent Change | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | -2.4 ± 1.51 | -3.0 ± 1.50 | -2.6 ± 1.50 | -5.1 ± 1.72 | -2.9 ± 1.76 | -1.4 ± 1.52 |
| Week 8 | -6.2 ± 2.03 | -5.4 ± 2.01 | -5.1 ± 2.01 | -6.6 ± 2.33 | -3.0 ± 2.32 | -5.8 ± 2.02 |
| Week 12 | -7.2 ± 2.44 | -11.9 ± 2.40 | -9.1 ± 2.40 | -11.4 ± 2.82 | -4.9 ± 2.76 | -8.0 ± 2.40 |
| Week 16 | -10.0 ± 2.66 | -13.1 ± 2.67 | -12.6 ± 2.66 | -11.9 ± 3.03 | -5.7 ± 3.03 | -12.0 ± 2.62 |
| Week 20 | -13.8 ± 3.13 | -16.0 ± 2.98 | -14.2 ± 3.07 | -12.0 ± 3.43 | -9.2 ± 3.51 | -13.3 ± 3.04 |
| Week 24 | -14.7 ± 3.49 | -19.2 ± 3.29 | -14.7 ± 3.44 | -14.0 ± 4.15 | -12.1 ± 3.88 | -11.0 ± 3.34 |
The central read F-VASI was assessed based on the facial photographs taken at the site. The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)×100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
| Percent Change | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0.1 ± 0.80 | 0.4 ± 0.82 | -0.2 ± 0.84 | -1.2 ± 0.94 | 0.0 ± 0.91 | 0.6 ± 0.83 |
| Week 8 | -7.0 ± 1.42 | -5.3 ± 1.44 | -1.8 ± 1.46 | -1.4 ± 1.62 | -0.1 ± 1.55 | -0.2 ± 1.44 |
| Week 16 | -17.0 ± 3.16 | -16.4 ± 3.25 | -10.7 ± 3.19 | -13.3 ± 3.87 | -5.6 ± 3.67 | -0.2 ± 3.27 |
| Week 24 | -21.2 ± 4.13 | -21.2 ± 4.16 | -18.5 ± 4.44 | -14.6 ± 5.47 | -3.0 ± 4.65 | 2.1 ± 4.06 |
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0.00 4.00): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percent Change | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | -4.9 ± 2.63 | 3.1 ± 2.61 | -5.0 ± 2.60 | 0.4 ± 2.96 | -5.3 ± 3.05 | -6.3 ± 2.63 |
| Week 8 | -11.3 ± 5.35 | 0.4 ± 5.32 | -8.8 ± 5.30 | 10.1 ± 6.09 | -7.3 ± 6.12 | -7.5 ± 5.31 |
| Week 12 | -15.9 ± 4.16 | -6.5 ± 4.11 | -12.2 ± 4.10 | -7.1 ± 4.77 | -9.8 ± 4.72 | -11.4 ± 4.08 |
| Week 16 | -19.4 ± 4.85 | -6.2 ± 4.88 | -19.7 ± 4.82 | -6.4 ± 5.48 | -10.3 ± 5.46 | -13.3 ± 4.75 |
| Week 20 | -21.9 ± 5.59 | -12.9 ± 5.35 | -23.2 ± 5.52 | 0.0 ± 6.11 | -14.4 ± 6.30 | -15.3 ± 5.44 |
| Week 24 | -28.3 ± 5.70 | -20.6 ± 5.38 | -26.2 ± 5.61 | -4.3 ± 6.70 | -13.9 ± 6.32 | -18.1 ± 5.43 |
The Self-Assessment Vitiligo Extent Score (SA-VES) was a validated patient report outcome measurement instrument to provide information about disease extent. Vitiligo Extent Score (VES) was a measure to express the overall vitiligo involvement of the body (extent). Clinical illustrations for 19 separate body areas that reflected different degrees of involvement (1%, 5%, 10%, 25%, 50% and 75% depigmentation) were chosen to represent the participant's skin lesions to get the total extent of the disease. VES was a sum of all surface measurement that was similar to VASI. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percent Change | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 2.7 ± 17.19 | 1.1 ± 16.71 | -1.1 ± 16.74 | 4.9 ± 19.25 | 4.9 ± 19.84 | 50.4 ± 17.13 |
| Week 16 | 4.7 ± 13.82 | -0.5 ± 13.48 | -3.7 ± 13.45 | 6.9 ± 15.53 | -0.5 ± 15.87 | 52.5 ± 13.72 |
| Week 24 | 0.0 ± 10.35 | -3.5 ± 10.02 | -4.3 ± 10.11 | -4.4 ± 11.89 | -1.6 ± 11.77 | 44.0 ± 10.16 |
The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. The absolute change from baseline in T-VASI was analyzed using the ANCOVA analysis. Negative change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Units on a Scale | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | -0.3 ± 0.25 | -0.5 ± 0.25 | -0.6 ± 0.25 | -1.0 ± 0.28 | -0.4 ± 0.29 | -0.2 ± 0.25 |
| Week 8 | -0.9 ± 0.32 | -0.9 ± 0.32 | -0.9 ± 0.32 | -1.2 ± 0.37 | -0.5 ± 0.36 | -0.9 ± 0.32 |
| Week 12 | -1.1 ± 0.41 | -2.0 ± 0.40 | -1.6 ± 0.40 | -1.8 ± 0.47 | -0.9 ± 0.46 | -1.6 ± 0.40 |
| Week 16 | -1.5 ± 0.46 | -2.1 ± 0.46 | -1.9 ± 0.46 | -1.9 ± 0.53 | -0.9 ± 0.53 | -2.2 ± 0.46 |
| Week 20 | -2.0 ± 0.55 | -2.8 ± 0.53 | -2.3 ± 0.54 | -2.0 ± 0.61 | -1.7 ± 0.62 | -2.2 ± 0.54 |
| Week 24 | -2.3 ± 0.62 | -3.4 ± 0.59 | -2.4 ± 0.61 | -2.7 ± 0.74 | -2.0 ± 0.69 | -1.8 ± 0.60 |
T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 1.6 | 1.5 | 0 | 2.0 | 0 | 0 |
| Week 8 | 1.6 | 1.5 | 1.5 | 4.0 | 0 | 1.5 |
| Week 12 | 1.6 | 1.5 | 1.5 | 4.1 | 0 | 4.5 |
| Week 16 | 0 | 3.2 | 0 | 2.1 | 0 | 6.3 |
| Week 20 | 4.9 | 1.5 | 1.6 | 6.1 | 2.1 | 9.5 |
| Week 24 | 7.9 | 4.6 | 4.6 | 10.6 | 4.1 | 9.1 |
T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 75% improvement from baseline in T-VASI (T-VASI75). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 24 | 0 | 0 | 0 | 0 | 0 | 0 |
T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 90% improvement from baseline in T-VASI (T-VASI90). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 24 | 0 | 0 | 0 | 0 | 0 | 0 |
T-VASI was calculated using a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = Ʃ \[Hand Units\] × \[Depigmentation\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. This outcome measure was the percentage of participants achieving 100% improvement from baseline in T-VASI (T-VASI100). Percent change from baseline in T-VASI = ((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)×100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 24 | 0 | 0 | 0 | 0 | 0 | 0 |
The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 50% improvement in central read F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 2.2 | 0 | 0 |
| Week 8 | 3.2 | 0 | 0 | 2.2 | 0 | 0 |
| Week 16 | 14.8 | 13.8 | 6.9 | 10.3 | 2.4 | 1.9 |
| Week 24 | 22.4 | 25.4 | 15.4 | 18.9 | 7.0 | 1.8 |
The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 75% improvement in central read F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 | 1.6 | 1.7 | 5.2 | 2.6 | 2.4 | 0 |
| Week 24 | 12.1 | 8.5 | 7.7 | 2.7 | 2.3 | 0 |
The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 90% improvement in central read F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 | 0 | 0 | 1.7 | 0 | 0 | 0 |
| Week 24 | 1.7 | 0 | 3.8 | 0 | 0 | 0 |
The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=Ʃ \[Affected Facial Surface Area\] × 4 × \[Depigmentation Rates\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)×100. This outcome measure was the percentage of participants achieving at least 100% improvement in central read F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18.
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 24 | 0 | 0 | 0 | 0 | 0 | 0 |
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 50% improvement in site assessment F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 3.1 | 3.0 | 1.5 | 2.0 | 0 | 3.0 |
| Week 8 | 9.4 | 3.0 | 4.5 | 2.0 | 4.1 | 4.5 |
| Week 12 | 16.1 | 9.1 | 9.1 | 8.2 | 8.3 | 9.1 |
| Week 16 | 14.3 | 9.7 | 13.6 | 8.5 | 10.6 | 14.3 |
| Week 20 | 18.0 | 14.9 | 17.2 | 12.2 | 16.7 | 17.5 |
| Week 24 | 20.6 | 21.5 | 15.4 | 10.6 | 18.4 | 16.7 |
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 75% improvement in site assessment F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 0 | 0 | 1.5 |
| Week 8 | 0 | 0 | 3.0 | 2.0 | 0 | 0 |
| Week 12 | 1.6 | 3.0 | 4.5 | 6.1 | 2.1 | 1.5 |
| Week 16 | 3.2 | 0 | 4.5 | 4.3 | 4.3 | 7.9 |
| Week 20 | 6.6 | 1.5 | 9.4 | 6.1 | 6.3 | 11.1 |
| Week 24 | 11.1 | 4.6 | 6.2 | 4.3 | 4.1 | 13.6 |
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving at least 90% improvement in site assessment F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 | 0 | 0 | 1.5 | 2.0 | 0 | 0 |
| Week 12 | 0 | 0 | 1.5 | 2.0 | 0 | 0 |
| Week 16 | 1.6 | 0 | 3.0 | 2.1 | 2.1 | 0 |
| Week 20 | 1.6 | 1.5 | 4.7 | 2.0 | 2.1 | 1.6 |
| Week 24 | 1.6 | 1.5 | 3.1 | 0 | 4.1 | 1.5 |
The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \[Digit Units\] × \[Depigmentation\] × 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)×100. This outcome measure was the percentage of participants achieving 100% improvement in site assessment F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 | 0 | 0 | 0 | 2.0 | 0 | 0 |
| Week 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 20 | 0 | 0 | 1.6 | 0 | 0 | 0 |
| Week 24 | 0 | 0 | 1.5 | 0 | 0 | 0 |
The Vitiligo-Specific Quality of Life (VitiQoL) instrument was a reliable and validated vitiligo disease-specific health-related quality of life (HRQoL) instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL total score was calculated as sum of items 1-15. The change from baseline in total VitiQoL score was analyzed using the mixed-effect models repeated measures (MMRM) analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Units on a Scale | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | -3.9 ± 1.34 | -2.9 ± 1.31 | -4.4 ± 1.31 | -4.4 ± 1.50 | -3.5 ± 1.54 | -5.1 ± 1.33 |
| Week 16 | -6.5 ± 1.83 | -4.9 ± 1.79 | -6.3 ± 1.82 | -4.8 ± 2.07 | -10.5 ± 2.06 | -7.1 ± 1.78 |
| Week 24 | -6.5 ± 1.99 | -3.6 ± 1.92 | -7.7 ± 1.99 | -7.0 ± 2.30 | -9.7 ± 2.22 | -6.4 ± 1.92 |
The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Participation Limitation domain score was the sum of items 3, 4, 6, 9, 10, 11, 14 and ranged from 0 to 42. The change from baseline in VitiQoL Participation Limitation Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Units on a Scale | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | -1.2 ± 0.71 | -1.1 ± 0.69 | -1.7 ± 0.69 | -1.8 ± 0.79 | -1.0 ± 0.81 | -2.5 ± 0.70 |
| Week 16 | -2.1 ± 0.88 | -1.9 ± 0.86 | -2.6 ± 0.87 | -2.3 ± 1.00 | -4.1 ± 0.99 | -3.1 ± 0.85 |
| Week 24 | -1.4 ± 0.98 | -1.7 ± 0.94 | -3.2 ± 0.97 | -2.8 ± 1.14 | -3.9 ± 1.09 | -2.2 ± 0.94 |
The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Stigma domain score was the sum of items 1, 2, 5, 7 and 15, and ranged from 0 to 30. The change from baseline in VitiQoL Stigma Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Units on a Scale | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | -1.9 ± 0.56 | -1.6 ± 0.55 | -2.4 ± 0.55 | -1.7 ± 0.62 | -1.7 ± 0.64 | -1.8 ± 0.56 |
| Week 16 | -3.4 ± 0.71 | -2.3 ± 0.70 | -3.2 ± 0.71 | -1.7 ± 0.80 | -4.3 ± 0.80 | -2.9 ± 0.69 |
| Week 24 | -3.8 ± 0.76 | -2.1 ± 0.73 | -3.7 ± 0.76 | -3.1 ± 0.88 | -4.5 ± 0.84 | -3.2 ± 0.73 |
The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from "not at all" (scored 0) to "most of the time" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Behaviors domain score was the sum of items 8, 12 and 13, and ranged from 0 to 18. The change from baseline in VitiQoL Behaviors Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Units on a Scale | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Week 4 | -0.8 ± 0.37 | -0.3 ± 0.36 | -0.2 ± 0.36 | -0.9 ± 0.41 | -0.7 ± 0.42 | -0.7 ± 0.37 |
| Week 16 | -1.1 ± 0.50 | -0.8 ± 0.49 | -0.5 ± 0.50 | -0.9 ± 0.57 | -2.1 ± 0.56 | -1.0 ± 0.49 |
| Week 24 | -1.4 ± 0.53 | 0 ± 0.52 | -0.7 ± 0.53 | -1.3 ± 0.62 | -1.3 ± 0.60 | -0.9 ± 0.51 |
The percentage of participants achieving a static Investigator Global Assessment (sIGA) Score 0/1 and sIGA ≥2-point improvement at Week 24 was presented in this outcome measure. The sIGA score ranged from 0 to 4. The sIGA Score 0 represented "Clear" with no signs of loss of pigmentation with natural light or with Woods lamp examination. The sIGA Score 1 represented "Almost Clear" with the following descriptors: * Faint, barely detectable loss of pigmentation mainly located on dorsal hands, feet, bony prominences, and/or limited areas. * Approximately 90% pigmentation within lesions. * No or rare signs of Koebner phenomenon, confetti like or trichrome lesions could be present. The sIGA Scores 2, 3 and 4 represented "Mild Vitiligo", "Moderate Vitiligo" and "Severe Vitiligo", respectively.
| Percentage of Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving sIGA 0 or 1 and at Least a 2-Point Improvement at Week 24 - DR Period | 0 | 0 | 0 | 0 | 0 | 0 |
Adverse Event (AE) was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator.
| Participants | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Participants With All-Causality TEAEs | 56 | 45 | 54 | 30 | 40 | 52 |
| Participants With Treatment-Related TEAEs | 32 | 19 | 20 | 17 | 18 | 20 |
| Participants With All-Causality SAEs | 0 | 0 | 1 | 1 | 1 | 1 |
| Participants With Treatment-Related SAEs | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Participants | PF-06651600 200mg - 50mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Participants With Anaemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants With Neutropenia | 0 | 1 | 0 | 0 | 1 | 1 |
| Participants With Thrombocytopenia | 1 | 0 | 0 | 0 | 0 | 0 |
| Participants With Lymphopenia | 1 | 0 | 0 | 0 | 0 | 0 |
Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator. Baseline was defined as the last measurement prior to first dosing (Day 1).
| Participants | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile up to Week 24 - DR Period | 0 | 0 | 0 | 0 | 0 | 0 |
Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin.
| Participants | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo |
|---|---|---|---|---|---|---|
| Bilirubin > 1.5 x upper limit of normal (ULN) | 0 | 0 | 0 | 0 | 0 | 0 |
| AST > 2.5 x ULN | 1 | 0 | 1 | 0 | 1 | 0 |
| ALT > 2.5 x ULN | 0 | 0 | 1 | 1 | 1 | 1 |
AE was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator.
| Participants | Extension (EXT) PF-06700841 60 mg - 30 mg QD | EXT PF-06651600 200 Mg-50 mg QD + nbUVB | EXT PF-06651600 200 mg - 50 mg QD | EXT PF-06651600 50 mg QD | EXT PF-06651600 30 mg QD |
|---|---|---|---|---|---|
| Participants With All-Causality TEAEs | 38 | 32 | 119 | 3 | 2 |
| Participants With Treatment-Related TEAEs | 20 | 12 | 36 | 0 | 0 |
| Participants With All-Causality SAEs | 1 | 0 | 1 | 0 | 0 |
| Participants With Treatment-Related SAEs | 1 | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.
| Participants | Extension (EXT) PF-06700841 60 mg - 30 mg QD | EXT PF-06651600 200 Mg-50 mg QD + nbUVB | EXT PF-06651600 200 mg - 50 mg QD | EX PF-06651600 50mg QD | EXT PF-06651600 30 mg QD |
|---|---|---|---|---|---|
| Participants With Anemia | 0 | 0 | 0 | 1 | 0 |
| Participants With Neutropenia | 1 | 0 | 1 | 0 | 0 |
| Participants With Thrombocytopenia | 0 | 0 | 0 | 0 | 0 |
| Participants With Lymphopenia | 0 | 0 | 0 | 0 | 0 |
Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator.
| Participants | Extension (EXT) PF-06700841 60 mg - 30 mg QD | EXT PF-06651600 200 Mg-50 mg QD + nbUVB | EXT PF-06651600 200 mg - 50 mg QD | EXT PF-06651600 50 mg QD | EXT PF-06651600 30 mg QD |
|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile - Ext Period | 0 | 0 | 0 | 0 | 0 |
Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin.
| Participants | Extension (EXT) PF-06700841 60 mg - 30 mg QD | EXT PF-06651600 200 Mg-50 mg QD + nbUVB | EXT PF-06651600 200 mg - 50 mg QD | EXT PF-06651600 50 mg QD | EXT PF-06651600 30 mg QD |
|---|---|---|---|---|---|
| Bilirubin > 1.5 x ULN | 0 | 0 | 0 | 0 | 0 |
| AST > 2.5 x ULN | 0 | 0 | 0 | 0 | 0 |
| ALT > 2.5 x ULN | 0 | 0 | 1 | 0 | 0 |
Collected over 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06651600 200 mg - 50 mg QD | 0/65 (0%) | 0/65 (0%) | 31/65 (47.7%) |
| PF-06651600 100 mg - 50 mg QD | 0/67 (0%) | 0/67 (0%) | 35/67 (52.2%) |
| PF-06651600 50 mg QD | 0/67 (0%) | 1/67 (1.5%) | 32/67 (47.8%) |
| PF-06651600 30 mg QD | 0/50 (0%) | 1/50 (2%) | 23/50 (46%) |
| PF-06651600 10 mg QD | 0/49 (0%) | 1/49 (2%) | 22/49 (44.9%) |
| Placebo | 0/66 (0%) | 1/66 (1.5%) | 37/66 (56.1%) |
| Extension (EXT) PF-06700841 60 mg - 30 mg QD | 0/55 (0%) | 1/55 (1.8%) | 17/55 (30.9%) |
| EX PF-06651600 200 mg - 50 mg QD + nbUVB | 0/43 (0%) | 0/43 (0%) | 14/43 (32.6%) |
| EX PF-06651600 200mg-50mg QD | 0/187 (0%) | 1/187 (0.5%) | 46/187 (24.6%) |
| EX PF-06651600 50mg QD | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| EXT PF-06651600 30 mg QD | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo | Extension (EXT) PF-06700841 60 mg - 30 mg QD | EX PF-06651600 200 mg - 50 mg QD + nbUVB | EX PF-06651600 200mg-50mg QD | EX PF-06651600 50mg QD | EXT PF-06651600 30 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MigraineNervous system disorders | 0/65 | 0/67 | 1/67 | 0/50 | 1/49 | 0/66 | 0/55 | 0/43 | 0/187 | 0/6 | 0/2 |
| Oesophageal spasmGastrointestinal disorders | 0/65 | 0/67 | 0/67 | 1/50 | 0/49 | 0/66 | 0/55 | 0/43 | 0/187 | 0/6 | 0/2 |
| Disseminated varicella zoster virus infectionInfections and infestations | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 0/66 | 1/55 | 0/43 | 0/187 | 0/6 | 0/2 |
| Neurogenic bladderRenal and urinary disorders | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 1/66 | 0/55 | 0/43 | 0/187 | 0/6 | 0/2 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 0/66 | 0/55 | 0/43 | 1/187 | 0/6 | 0/2 |
| Event | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo | Extension (EXT) PF-06700841 60 mg - 30 mg QD | EX PF-06651600 200 mg - 50 mg QD + nbUVB | EX PF-06651600 200mg-50mg QD | EX PF-06651600 50mg QD | EXT PF-06651600 30 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BronchitisInfections and infestations | 0/65 | 1/67 | 1/67 | 3/50 | 0/49 | 0/66 | 1/55 | 0/43 | 0/187 | 0/6 | 1/2 |
| Urinary tract infectionInfections and infestations | 4/65 | 4/67 | 2/67 | 2/50 | 3/49 | 3/66 | 1/55 | 3/43 | 12/187 | 1/6 | 1/2 |
| COVID-19Infections and infestations | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 0/66 | 0/55 | 0/43 | 2/187 | 0/6 | 1/2 |
| OnychomycosisInfections and infestations | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 0/66 | 0/55 | 0/43 | 0/187 | 0/6 | 1/2 |
| RashSkin and subcutaneous tissue disorders | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 0/66 | 0/55 | 1/43 | 1/187 | 0/6 | 1/2 |
| NasopharyngitisInfections and infestations | 8/65 | 10/67 | 16/67 | 5/50 | 5/49 | 14/66 | 3/55 | 0/43 | 8/187 | 0/6 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 0/66 | 0/55 | 0/43 | 0/187 | 1/6 | 0/2 |
| Ear painEar and labyrinth disorders | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 0/66 | 0/55 | 0/43 | 0/187 | 1/6 | 0/2 |
| Influenza like illnessGeneral disorders | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 0/66 | 0/55 | 0/43 | 0/187 | 1/6 | 0/2 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/65 | 0/67 | 0/67 | 0/50 | 0/49 | 0/66 | 0/55 | 0/43 | 0/187 | 1/6 | 0/2 |
Baseline analysis population included all participants who received at least 1 dose of randomized study medication and had a baseline and at least 1 post-baseline measurement (after taking randomization study medication).
| Age, Customized(Participants) | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo | Total |
|---|---|---|---|---|---|---|---|
| <18 Years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 - 44 Years | 33 | 29 | 33 | 20 | 16 | 30 | 161 |
| 45 - 64 Years | 30 | 37 | 34 | 30 | 31 | 32 | 194 |
| ≥65 Years | 2 | 1 | 0 | 0 | 2 | 4 | 9 |
| Sex: Female, Male(Participants) | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 30 | 31 | 39 | 28 | 25 | 40 | 193 |
| Male | 35 | 36 | 28 | 22 | 24 | 26 | 171 |
| Ethnicity (NIH/OMB)(Participants) | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 9 | 11 | 12 | 7 | 7 | 57 |
| Not Hispanic or Latino | 54 | 58 | 54 | 38 | 41 | 58 | 303 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 1 | 1 | 4 |
| Race (NIH/OMB)(Participants) | PF-06651600 200 mg - 50 mg QD | PF-06651600 100 mg - 50 mg QD | PF-06651600 50 mg QD | PF-06651600 30 mg QD | PF-06651600 10 mg QD | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 15 | 17 | 17 | 5 | 11 | 21 | 86 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 0 | 4 | 1 | 2 | 10 |
| White | 44 | 47 | 45 | 39 | 33 | 38 | 246 |
| More than one race | 0 | 1 | 1 | 0 | 2 | 1 | 5 |
| Unknown or Not Reported | 3 | 2 | 4 | 1 | 2 | 4 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Nov 2018 to primary completion in Feb 2021, 26 months.
Results were first posted in Mar 2022, 1 year 1 month after primary completion.
Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 26 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PF-06651600 · PF-06700841